Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases. The Company has a robust pipeline of novel, first-in-class, small molecules called pharmacological chaperones for the treatment of lysosomal storage diseases (LSDs). These chaperones may offer a dual-treatment approach for Fabry, Pompe, Gaucher and other LSDs. As orally administered monotherapy agents, pharmacological chaperones are designed to bind to, stabilize and increase the activity of a patient’s own misfolded enzyme. In combination with enzyme replacement therapy (ERT), pharmacological chaperones may improve the uptake of the infused enzyme and potentially improve ERT outcomes.

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. They help people with debilitating and complex conditions that are often difficult to diagnose and treat. They are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, they also established ourselves as a leader in the field of multiple sclerosis. In 2016, their focus expanded to include Sanofi’s programs in oncology and immunology. Their approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, they rapidly grew to become one of the world’s leading biotechnology companies, recognized for their pioneering development of treatments for rare genetic disorders and their innovative contributions to medical science and biomanufacturing.

Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA.

Hamlet Protein AS provides soya based protein solutions for specialty feed. It promotes health and efficiency in animal nutrition through functional ingredients and service. The firm provides products comprising desired properties in the feed for piglets, calves, pets, poultry, and aquatic animals. The bioconversion process developed from its very conception targeted towards the needs in animal feed. The company was founded by Ole Kaae Hansen in 1992 and is headquartered in Horsens, Denmark.

Clasado Ltd. is a private company headquartered in Wolverton, UK. The firm provides solutions for food, healthcare and pharmaceutical companies across the global wellness market.

Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA.

UCLB is the commercialisation company of UCL and its partner NHS Trusts. They bring to market truly world-leading, world-changing technologies, innovations that have a real and positive impact on people’s lives. UCLB the access point to the wealth of innovation and intellectual property emanating from UCL and partner hospitals including University College Hospital, Great Ormond Street Hospital, Royal Free Hospital and Moorfields Eye Hospital. They offer a number of services to assist the technology development process, from consultancy through to collaborative research, IP licensing and the creation of spinout companies and joint ventures to maximise the commercial potential of new discoveries, materials and processes.

Master Supplements, Inc. engages in the research and development of probiotic formulations and bioactive prebiotics. It offers its products under the Theralac, TruBifido, TruFlora, Granular, TheralacPRO, TruBifidoPRO, TruFiber, and Enzalase brands. The company was founded by Randolph S. Porubcan in 2002 and is headquartered in Victoria, MN.

Sansho Co., Ltd. is a Japanese private company with a presence in Thailand that engages in research & development, manufactures and distributes of pharmaceutical and cosmetic products.

JCR Pharmaceuticals Co., Ltd. engages in the manufacture and sale of pharmaceutical products. It operates through the following segments: Pharmaceutical Business; and Medical and Research Equipment Business. The Pharmaceutical Business segment deals with the manufacture, purchase, and sale of ethical drugs, active pharmaceutical ingredients, and raw materials. The Medical and Research Equipment Business segment sells medical devices and laboratory equipment. The company was founded by Shin Ashida on September 13, 1975 and is headquartered in Ashiya, Japan.

Velico Medical,, a pre-clinical medical technology company, develops and commercializes products for use in preparing and storing platelets and plasma, including a companion instrument and disposable product for spray drying plasma. The company offers FrontlineODP (On Demand Plasma), a technology to enable blood centers to prepare plasma in a dried powder format instead of freezing it; and FrontlinePPS (Platelet Protection System), a platelet protection technology for mitigating storage-related platelet deterioration. Velico Medical, was formerly known as ZymeQuest. The company was incorporated in 1991 and is based in Beverly, Massachusetts.

Tokyo Metropolitan Institute of Medical Science is a Japanese private company. The firm operates as a research institute that develops medicine.

Sangamo BioSciences is a clinical stage biopharmaceutical company involved in gene therapy that is researching ways of commercializing Zinc finger nucleases which modify a cell's DNA at an exact location thereby correcting or disrupting a specific gene. Sangamo BioSciences' lead therapy, SB-728, is a potential functional cure for HIV/AIDS. SB-728 works by removing some of the immune cells from the patient's blood that HIV attacks. The blood is sent to a lab which applies the SB-728 treatment to the patient's immune cells. The treatment removes the protein gateway on the immune cells that HIV needs to infect. The treated cells are then infused back into the patient whereby they reproduce and take over as HIV attacks and kills the non-treated cells. The treated, resistant cells thereby control the HIV infection and thus cures the patient from opportunistic infections that result from HIV. Recent published data further support the company's ongoing progress which has been described as "a major step toward immunological functional control of HIV."

Part of BIOTRONIK SE & Co. KG, Biotronik AG is a Swiss company located in Bulach that manufactures devices for vascular intervention and electrotherapy of heart.\nThe company says this about itself: BIOTRONIK is a leading medical device company that has been developing trusted and innovative cardiovascular and endovascular solutions for more than 50 years. Driven by a purpose to perfectly match technology with the human body, BIOTRONIK innovations deliver care that saves and improves the lives of millions diagnosed with heart and blood vessel diseases every year. BIOTRONIK is headquartered in Berlin, Germany, and represented in over 100 countries.

Alfasigma is a major group that has accepted an important challenge: finding solutions to cure the population each and every day. Alfasigma products are appreciated throughout the world. Technology, enthusiasm and specific expertise have ensured continuous growth and steady internationalization. Four graphics are presented below that illustrate the progress of the group in Italy and the world.

Clearant, Inc. produces tissue allograft implants, plasma therapies, blood and recombinant products. The company was founded on April 30, 1999 and is headquartered in Orlando, FL.